IFPMA Facts and Figures Report
Related news and resources
Financing health systems: Leveraging the benefits of investing in prevention against NCDs
Investing in the prevention and treatment of non-communicable diseases (NCDs) can strengthen health systems, protect economic productivity, and improve population wellbeing. Evidence shows that every dollar invested in preventing and managing NCDs generates substantial returns through reduced healthcare costs, improved workforce participation, and healthier, more resilient societies. Yet despite this compelling investment case, progress remains...
Read more158th session of the WHO Executive Board (EB158): Priorities for financing noncommunicable diseases to achieve universal health coverage
On 2 February 2026, PATH delivered a joint constituency statement on Agenda itea 6: Follow-up to the political declaration of the high-level meeting of the General Assembly on the prevention and control of non-communicable diseases at the 158th session of the WHO Executive Board. Sustainable and responsible financing—powered by multisectoral collaboration—is key to meet the...
Read moreThe innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines
IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.
Read more